Table 2.
Clinical trials involving the endocannabinoid system in the period 2009–2018.
| Study name | Year Country | ECS target component | Objective or outcome | References |
|---|---|---|---|---|
| Titration Study of ABX-1431 | 2018 Belgium | MAGL inhibitor | Assessment of safety, tolerability, pharmacodynamics and pharmacokinetics | https://clinicaltrials.gov/ct2/show/NCT03447756 |
| Pilot trial assessing efficacy and safety of medicinal cannabis in patients with gliomas | 2016 Australia | Exocannabinoid | Assessment of progression-free survival | https://www.endeavour.edu.au/about-us/news/impact-of-medicinal-cannabis-on-australians-with-malignant-brain-tumours |
| A double-blind, randomized, placebo-controlled, combined single and multiple ascending dose study of BIA 10-2474 | 2015 France | FAAH inhibitor | One exitus, five volunteers hospitalized with neurological side-effects | https://www.youscribe.com/BookReader/Index/2691486/?documentId=2855144 |
| Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol | 2015 United Kingdom | Exocannabinoid | Reduction in circulating tumor cells/reduction in tumor size | Anticancer Res. 2018, 38(10):5831–5835 |
| A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients | 2014 United Kingdom and Germany | Exocannabinoid | Improved survival rate | https://clinicaltrials.gov/ct2/show/NCT01812616 |
| A study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme | 2013 United Kingdom | Exocannabinoid | Some efficacy in patients with recurrent GBM as an adjunct to dose-intense temozolomide | J Clinical Oncol, 2017, 35(15)suppl:2046 |
| Dexanabinol in Patients With Brain Cancer | 2012 United States | Exocannabinoid | Assess the effect on tumor size | https://clinicaltrials.gov/ct2/show/NCT01654497 |
| A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumors | 2011 United Kingdom | Exocannabinoid | Asses the reduction in size of tumor(s) | https://clinicaltrials.gov/ct2/show/study/NCT01489826 |
| A population-based case-control study of marijuana use and head and neck squamous cell carcinoma | 2009 United States | Exocannabinoid | Moderate marijuana use is associated with reduced risk of HNSCC | Cancer Prev Res (Phila Pa). 2009, 2(8):759–68 |